Miacalcin (Calcitonin-salmon) Endocrine/Metabolic Posterior pitutary hormone Paget's Disease of Bone (osteitis deformans), hypercalcemis, osteogenesis imperfecta, postmenopausal osteoperosis in women >5 years postmenopause with low bone mass as alternative to estrogen. 1 spray daily, alternating nostrils. Category C. Flushing, nausea, allergic reactions, local irritation, edema of feet, eye pain, increased uninary frequency, pruitius of ear lobes. Pregnancy Risk Categories defined: A: Studies in pregnant women failed to show a risk to the fetus in the first trimester - with no evidence of risk in the later trimesters. B: Animals studies indicate no adverse effect to the fetus, but there are no adequate, clinical studies in pregnant women. C: Animal studies have shown an adverse effect on the fetus, but there are no adequate, clinical studies in humans. Despite potential risks, the drug may be useful in pregnant women. D: There is evidence of risk to the human fetus, but the potential benefits of use in pregnant women may be acceptable, despite potential risks. X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any potential benefit from using the drug in pregnant women, regardless of trimester. NR: Not rated (i.e., no information available at this time as to the potential risks or benefits).